In Q3 2024, Tang Capital Management held 116 positions worth $1.2B. They initiated 24 new positions and exited 54. Their largest holding was EOLS ($78.5M). Portfolio value grew +43.3% versus the prior quarter.
Frequently asked questions
What stocks did Tang Capital Management own in Q3 2024?
Tang Capital Management held 116 biotech stocks in their 13F portfolio in Q3 2024. Their top positions include EOLS, TARS, AUPH, MIRM, KALV. The full holdings table is available on BiotechEdge with position sizes, quarter-over-quarter changes, and AI analysis.
How much was Tang Capital Management's portfolio worth in Q3 2024?
Tang Capital Management's tracked biotech portfolio was worth $1.2B across 116 positions, with total assets under management of approximately $2B. Portfolio values are based on 13F filings with the SEC.
What did Tang Capital Management buy in Q3 2024?
Tang Capital Management initiated 24 new positions in Q3 2024, including BNTX, RLAY, NBIX, NVAX, CRBP and 19 more. They also increased 35 existing positions.
What did Tang Capital Management sell in Q3 2024?
Tang Capital Management fully exited 54 positions in Q3 2024, including SCYX, RXDX, TIL, FHN-PH, RCUS and 49 more. They also trimmed 9 existing positions.
Is Tang Capital Management a biotech fund?
Event-driven biotech specialist known for concentrated bets around clinical catalysts, M&A situations, and activist campaigns. Deep industry relationships and willingness to engage publicly make the fund a closely watched market signal.
Want AI analysis, insider signals, and catalyst overlays for Tang Capital Management?
View latest Tang Capital Management portfolio →